Patents by Inventor Pierre-Joseph ROYER

Pierre-Joseph ROYER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for predicting chronic lung allograft dysfunction
    Patent number: 11814683
    Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 14, 2023
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique, Université de Nantes, Centre Hospitalier Universitaire de Nantes
    Inventors: Pierre-Joseph Royer, Antoine Magnan, Sophie Brouard, Richard Danger
  • Methods and compositions for predicting chronic lung allograft dysfunction
    Patent number: 11421277
    Abstract: The present invention relates to a method for predicting the risk of having the CLAD in a subject by measuring the expression level of TCL1A in a biological sample obtained from said subject. Inventors have used a large-scale gene expression profiling of whole blood cells to identify early biomarkers of BOS. Microarray experiments performed from 80 patients (40 stable (STA) and 40 BOS) identified 47 genes differentially expressed between STA and BOS recipients. An independent set of patients (13 STA, 11 BOS) was then used for external validation by qPCR. T-cell leukemia/lymphoma protein 1A (TCL1A) gene was identified and validated as a predictive marker of BOS more than 6 months before diagnosis with area under curve of 0.77. Accordingly, the invention relates to a method for predicting the risk of having the chronic lung allograft dysfunction (CLAD) and to a method for preventing the risk of having CLAD by administering immunosuppressive drugs.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: August 23, 2022
    Assignees: INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Richard Danger, Sophie Brouard, Pierre-Joseph Royer, Antoine Magnan
  • METHODS AND COMPOSITIONS FOR PREDICTING CHRONIC LUNG ALLOGRAFT DYSFUNCTION
    Publication number: 20210404000
    Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.
    Type: Application
    Filed: March 9, 2021
    Publication date: December 30, 2021
    Inventors: Pierre-Joseph ROYER, Antoine MAGNAN, Sophie BROUARD, Richard DANGER
  • Methods and Compositions For Predicting Chronic Lung Allograft Dysfunction
    Publication number: 20210139989
    Abstract: The present invention relates to a method for predicting the risk of having the CLAD in a subject by measuring the expression level of TCL1A in a biological sample obtained from said subject. Inventors have used a large-scale gene expression profiling of whole blood cells to identify early biomarkers of BOS. Microarray experiments performed from 80 patients (40 stable (STA) and 40 BOS) identified 47 genes differentially expressed between STA and BOS recipients. An independent set of patients (13 STA, 11 BOS) was then used for external validation by qPCR. T-cell leukemia/lymphoma protein 1A (TCL1A) gene was identified and validated as a predictive marker of BOS more than 6 months before diagnosis with area under curve of 0.77. Accordingly, the invention relates to a method for predicting the risk of having the chronic lung allograft dysfunction (CLAD) and to a method for preventing the risk of having CLAD by administering immunosuppressive drugs.
    Type: Application
    Filed: June 26, 2018
    Publication date: May 13, 2021
    Inventors: Richard DANGER, Sophie BROUARD, Pierre-Joseph ROYER, Antoine MAGNAN
  • Methods and compositions for predicting chronic lung allograft dysfunction
    Patent number: 10975438
    Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: April 13, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE NANTES, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Pierre-Joseph Royer, Antoine Magnan, Sophie Brouard, Richard Danger
  • METHODS AND COMPOSITIONS FOR PREDICTING CHRONIC LUNG ALLOGRAFT DYSFUNCTION
    Publication number: 20190226027
    Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 25, 2019
    Inventors: Pierre-Joseph ROYER, Antoine MAGNAN, Sophie BROUARD, Richard DANGER